Intramuscular Interferon Beta-1a Therapy Initiated During a First Demyelinating Event in Multiple Sclerosis
NEJM 343:898-904, Jacobs,L.D. et al, 2000

Progressive Forms of MS:Classification Streamlined or Consensus Overturned?
Lancet 355:162-163, Weinshenker,B.G., 2000

Effect of Interferon B-1b in MS, Assessment of Annual Accumulation of PD/T2 Activity on MRI
Neurol 54:200-206, Zhao,G.J.,et al, 2000

A Comparison of Continuous Thalamic Stimulation and Thalamotomy for Suppression of Severe Tremor
NEJM 342:461-468,505, Schuurman,P.R.,et al, 2000

Autosomal Dominant Diffuse Leukoencephalopathy with Neuroaxonal Spheroids
Neurol 54:463-468, van der Knaap,M.S.,et al, 2000

Amyotrophic lateral Sclerosis Mimic Syndromes, A Population-Based Study
Arch Neurol 57:109-113, Traynor,B.J.,et al, 2000

Total Brain N-Acetylaspartate, A New Measure of Disease Load in MS
Neurol 54:15-19, Gonen,O.,et al, 2000

Distribution of Cranial MRI Abnormalities in Patients with Symptomatic and Subclinical CADASIL
BJR 73:256-265, Coulthard, A.,et al, 2000

Traumatic Brain Injury:Diffusion-Weighted MR Imaging Findings
AJNR 20:1636-1641, Liu,A.Y.,et al, 1999

Incidental Detection of Hippocampal Sclerosis on MR Images:Is It Significant?
AJNR 20:1609-1612,1575, Moore,K.R.,et al, 1999

Population Based Cost Utility Study of Interferon Beta-1b in Secondary Progressive Multiple Sclerosis
BMJ 319:1529-1533, Forbes,R.B.,et al, 1999

Suppression of Pendular Nystagmus by Smoking Cannabis in a Patient with Multiple Sclerosis
Neurol 53:2209-2210, Schon,F.,et al, 1999

Gastric Tolerance of High-Dose Pulse Oral Prednisone in Multiple Sclerosis
Neurol 53:2093-2096, Metz,L.M.,et al, 1999

Relevance of Hypointense Lesions on Fast Fluid-Attenuated Inversion Recovery MR Images as a Marker of Disease Severity in Cases of Multiple Sclerosis
AJNR 20:813-820, Rovaris,M.,et al, 1999

Medial Temporal Lobe Atrophy on MRI in Dementia with Lewy Bodies
Neurol 52:1153-1158, Barber,R.,et al, 1999

Magnetic Resonance Imaging-Based Volumetry Differentiates Idiopathic Parkinson's Syndrome from Multiple System Atrophy and Progressive Supranuclear Palsy
Ann Neurol 45:65-74, Schulz,J.B.,et al, 1999

Magnetization Transfer Imaging of Patients with Definite MS and Negative Conventional MRI
Neurol 52:845-848, Filippi,M.,et al, 1999

Primary and Transitional Progressive MS,A Clinical and MRI Cross-Sectional Study
Neurol 52:839-845, Stevenson,V.L.,et al, 1999

Development of Hypointense Lesions on T1-Weighted Spin-Echo Magnetic Resonance Images in Multiple Sclerosis,Relation to Inflammatory Activity
Arch Neurol 56:345-351, van Walderveen,M.A.A.,et al, 1999

A Woman Who Left Her Wheelchair
Lancet 353:806, Mingrone,G.,et al, 1999

Multiple Sclerosis Associated with Uveitis in Two Large Clinic-Based Series
Neurol 52:179-181, Biousse,V.,et al, 1999

Clinicopath Conf,Wegener's Granulomatosis with Pachymeningeal Granulomatous Inflammation, Case 9-1999
NEJM 340:945-953, , 1999

Interferon-alpha 2a Reduces MRI Disease Activity in Relapsing-Remitting Multiple Sclerosis
Neurol 52:1049-1056, Myhr,K.M.,et al, 1999

Quantitative MRI in CADASIL, Correlation with Disability and Cognitive Performance
Neurol 52:1361-1367, Dichgans,M.,et al, 1999

A New Metabolite Contributing to N-Acetyl Signal in 1H MRS of the Brain in Salla Disease
Neurol 52:1668-1672, Varho,T.,et al, 1999

Fibromyalgia Syndrome a Decade Later
Arch Int Med 159:777-785, Goldenberg,D.L., 1999

Neurology and the Skin
JNNP 66:417-430, Hurko,O.&Provost,T.T., 1999

Burden of Migraine in the United States, Disability and Economic Costs
Arch Int Med 159:813-818, Hu,X.H.,et al, 1999

Changes in Resource Use and Outcomes for Patients with Migraine Treated with Sumatriptan, A Managed Care Perspective
Arch Int Med 159:857-863, Lofland,J.H.,et al, 1999

Atypical Form of Amyotrophic Lateral Sclerosis
JNNP 66:581-585, Sasaki,S.&Iwata,M., 1999

Practice Parameter:The Care of the Patient with Amyotrophic Lateral Sclerosis (An Evidence-Based Review), Report of the Quality Standards Subcommittee of the AAN
Neurol 52:1311-1323, Miller,R.G.,et al, 1999

Efficacy, Safety, and Tolerance of the Non-Ergoline Dopamine Agonist Pramipexole in the Treatment of Advanced Parkinson's Disease:A Double Blind, Placebo Controlled, Randomised, Multicentre Study
JNNP 66:436-441, Pinter,M.M.,et al, 1999

Sjogren-Larsson Syndrome, Clinical and MRI/MRS Findings in FALDH-Deficient Patients
Neurol 52:1345-1352,1307, Van Domburg,P.H.M.F.,et al, 1999

Trigeminal Neuralgia Triggered by Auditory Stimuli in Multiple Sclerosis
Arch Neurol 56:731-733, Hartmann,M.,et al, 1999

Ibuprofen Treatment Versus Gradual Introduction of Interferon B-1b in patients with MS
Neurol 52:1893-1895, Rice,G.P.A.,et al, 1999

Cavernous Haemangioma Mimicking Multiple Sclerosis
BMJ 318:1604-1605, Cader,M.Z.&Winer,J.B., 1999

Cerebrospinal Fluid Findings in CADASIL
Neurol 53:233, Dichgans,M.,et al, 1999

Lamotrigine Adjunctive Therapy in painful Phenomena in MS:Preliminary Observations
Neurol 53:433, Cianchetti,C.,et al, 1999

Encephalitis after Hepatitis B Vaccination, Recurrent Disseminated Encephalitis or MS?
Neurol 53:396-401, Tourbah,A.,et al, 1999

Molecular Basis of the Neurodegenerative Disorders
NEJM 340:1970-1980, Martin,J.B., 1999

Chlamydia Pneumoniae Infection of the Central Nervous System in Multiple Sclerosis
Ann Neurol 46:6-14,4, Sriram,S.,et al, 1999

A Prospecitve Study of Preferences and Actual Treatment Choices in ALS
Neurol 53:278-283,248, Albert,S.M.,et al, 1999

A Longitudinal Study of Brain Atrophy in Relapsing Multiple Sclerosis
Neurol 53:139-148, Simon,J.H.,et al, 1999

Multiple Sclerosis in Children Under 6 Years of Age
Neurol 53:478-484, Ruggieri,M.,et al, 1999

Benign Multiple Sclerosis? Clinical Course, Long Term Follow Up, and Assessment of Prognostic Factors
JNNP 67:148-152,138, Hawkins,S.A.&McDonnell,G.V., 1999

Magnetic Resonance Imaging Results of the PRISMS Trial:A Randomized, Double-Blind, Placebo-Controlled Study of Interferon-B1a in Relapsing-Remitting Multiple Scleroosis
Ann Neurol 46:197-206, Li,D.K.B.,et al, 1999

Chronic Thalamic Stimulation for the Tremor of Multiple Sclerosis
Neurol 53:625-628, Montgomery,E.B.,et al, 1999

Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999

Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999

Recent Advances, Neurology
BMJ 319:362-366, Larner,A.J.&Farmer,S.F., 1999